OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1, a Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy

NEXT STORY
Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
PREV STORY
Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year running
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthcare Costs When Used to Treat High-Risk Patients with Cardiovascular Disease or Diabetes and Other Risk Factors

author_avatar
NASDAQ Market News

Global Digital Health Market to Surpass $1,045.8 Million, Growing with a CAGR of 33.4% from 2020 to 2027, Post-COVID-19 Turmoil – Exclusive Report [320 pages] by Research Dive

author_avatar
NASDAQ Market News

Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates

author_avatar
NASDAQ Market News